Biased Ligands. Better Drugs.

Trevena to Present at the Oppenheimer 27th Annual Healthcare Conference
3/14/17

Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 1:35 p.m. EDT in New York.

To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.

About Trevena

Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.

Contacts

Trevena, Inc.

Investors:
Jonathan Violin, Ph.D.
Sr. Director, Investor Relations
610-354-8840 x231
jviolin@trevena.com

or

Media:
Public Relations
PR@trevena.com

 

Copyright © Trevena, Inc.